Interestingly, among 18 follow-up patients, all 3 individuals who tested positive for both ATA and anti-PRMT5 antibody experienced ILD progression and fulfilled the criteria of PF-ILD within the preceding 24-month follow-up. This evidence concerns the gene PRMT5 and interstitial lung disease.